Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,994 total articles
Broadcom's pullback is a buying window. The company combines high-margin semiconductor franchises with sticky infrastructure software, produces $32.8B in free cash flow, and trades well below its 52-week high despite dominant AI infrastructure positioning. This trade gives a clear entry at $388.00, a $450 target, and a $360 stop - sized for a mid-t…
Applied Industrial Technologies has the balance-sheet resilience, cash generation, and engineered-solutions growth profile that make it more than a commodity distributor. That said, the stock is trading near its 52-week high, at a premium multiple (PE ~31) and stretched technicals. This trade idea looks to buy a measured pullback into value rather …
Aduro Clean Technologies is advancing technical validation and commercial partnerships for its Hydrochemolytic Technology (HCT). With a market cap of roughly $525M, a tight float and visible near-term catalysts, the setup supports a mid-term swing trade: buy ADUR at $14.26, target $18.50, stop $12.50. The plan leans on upcoming HCT test results, FO…
BGC Group appears positioned to extend a multi-quarter recovery driven by trading volume normalization, recurring data & analytics subscriptions, and disciplined cost control. We lay out a trade for a measured long with an entry at $28.50, a stop at $24.00, and a target of $36.00 over the next 180 trading days, balancing upside from revenue and mar…
GE Vernova reported a Q2 that — when you strip away noise — strengthens the structural case: a massive order backlog, strong free cash flow, low leverage and direct partnerships tied to AI data-center buildouts. I am raising my price target to reflect continued execution and accelerating 'behind-the-meter' power demand, but the valuation is rich an…
Connect Biopharma (CNTB) is a small-cap clinical-stage company developing rademikibart, an anti-IL-4Rα antibody positioned to deliver rapid lung-function gains for acute asthma and COPD exacerbations. With a market cap of ~$138.5M, a recent $20.2M placement and $46M cash on the balance sheet, the stock is trading near $2.20. The setup: upcoming rea…
Advanced Micro Devices is executing on a 'full-stack' AI strategy that pairs CPUs, GPUs, memory and system designs. Recent partnership news and product wins make a tactical long attractive into earnings and early Helios deployments, but the stock carries a premium valuation and execution must follow. This trade plan balances upside from share gains…
Renesas Electronics looks positioned for a re-rating after acquiring meaningful Wolfspeed assets and riding secular growth in automotive and power semiconductors. With a $50.9B market cap, a depressed earnings multiple, and manageable technicals, we upgrade to Buy for a mid-term trade targeting a rebound toward $15.50.
Exagen is a tiny diagnostics company focused on autoimmune and inflammatory disease testing. The setup is a classic small-cap biotech/diagnostics trade: limited revenue scale today, meaningful upside if adoption, reimbursement, or a commercial partnership accelerates growth, and significant downside from dilution or regulatory setbacks. This trade …
American Resources (AREC) is showing incremental operational progress and catalytic optionality through its ReElement rare-earth business. With a sub-$250M market cap, improving production metrics, and recent financing firepower, the stock is positioned for a re-rate if execution continues. Maintain Buy: enter around current levels, stop tight unde…
Red Cat is riding meaningful defense momentum: contract wins, field-trial validation and sector tailwinds are driving rapid volume and volatility. Fundamentals show a cash cushion per share but large negative free cash flow and persistent losses that make future dilution likely. This trade idea buys the current dip with a tight stop and a mid-term …
Atlassian's shares trade like a fading SaaS story while the company quietly converts AI investments into higher-value enterprise workloads and cash generation. With a $21.7B market cap, $1.20B in free cash flow and a P/S near 3.7, TEAM offers a high-conviction long with asymmetric risk/reward over the next 180 trading days.
Dollar General (DG) is mid-rerating after visible margin improvement, consistent free cash flow and a favorable footprint in price-sensitive markets. Recent Q1 results and guidance lift the fundamental base, valuation is still reasonable (EV/EBITDA ~9.1, P/E ~18), and technicals support a measured long. Entry $121, stop $110, target $140 over a lon…
Materialise (MTLS) is a profitable way to play a maturing 3D-printing specialist that is shifting mix toward higher-margin software and medical solutions. The stock trades at $6.50 with a market cap of roughly $387M and a PE of 33.6. We like a mid-term long trade targeting $8.00 with a $5.80 stop based on improving industry fundamentals, manageable…
Praxis (PRAX) is trading at roughly $315 and a market cap near $8.8B despite late-stage momentum across multiple CNS programs and an upcoming FDA decision window. I view the stock as materially undervalued versus plausible commercial outcomes and lay out a long trade with entry, stop and a two-step target plan over a 180-trading-day horizon.
Golconda Gold has started mining at Princeton Top and management is preparing a project spin-off that could materially narrow an apparent NAV discount. Technicals are constructive and short interest is elevated — set up a mid-term swing trade: enter at $1.50, target $2.20, stop $1.10. Time the trade for the next 45 trading days as spin-off news and…
Annaly offers a rare combination in the mortgage REIT space: a double-digit yield supported by rising earnings and portfolio growth. With a market cap near $16.4B, P/E around 8x and P/B roughly 1x, the stock looks attractively valued for a swing trade that collects income while waiting for spread normalization. Trade plan: enter $22.40, stop $20.50…
Tradeweb is a high-margin marketplace exposed to fixed income electronic trading and institutional flow. With $1.1B in free cash flow, durable revenue acceleration, and a conservative valuation setup, the stock can climb to $163.20 (about 65% upside) over the next 180 trading days if volumes normalize and multiple expansion follows. This trade lays…
monday.com's AI Work Platform and rising enterprise adoption could let the company move from work-management tool to a governance layer across enterprise tooling. Fundamentals remain solid (24% revenue growth, expanding enterprise customers, profitability improvements) while the stock trades at an attractive ~2.6x implied P/S on FY26 guidance. This…
Summit Therapeutics (SMMT) is a buy into the 11/14/2026 PDUFA for ivonescimab. The drug’s Phase 3 program showed an overall survival benefit versus chemotherapy and partner data have been described as impressive, giving the stock a clear binary upside if the FDA grants approval. The company’s current market cap is ~$12.1B while the fundamentals sho…
<p>Universal Music Group's core asset is intellectual property: recorded masters and publishing. That ownership creates recurring cashflow that is resilient to cycles in advertising and live performance, and today there are fresh distribution and licensing levers available to expand revenue per song. This idea lays out a long trade with defined ris…
VinFast is executing the geographic pivot I expected: factory expansion in Southeast Asia, product launches in India, and partnerships on autonomy and charging. The stock is inexpensive on a market-cap basis relative to growth optionality at $7.37B market cap, technicals show constructive momentum, and short interest remains elevated — creating asy…
Fortress Biotech (FBIO) trades at a market capitalization that looks to underappreciate its liquid assets, newly realized sale proceeds and recurring royalty streams. The stock is volatile and speculative, but the combination of a net cash-heavy balance sheet (enterprise value negative), an ongoing commercial launch and a 2.5% royalty on an FDA-app…
Centene (CNC) looks attractively valued on cash flow metrics despite membership declines. We lay out a long trade targeting $75 with a $61 stop, arguing that Medicare rate increases, cost cutting and a $7.1B FCF cushion give the company time to rebase margins and membership. The plan is for a long-term hold of roughly 180 trading days while watchin…
Cytokinetics' MYQORZO (aficamten) has cleared the hardest step - FDA approval and initial commercial launch - and early revenue and prescribing patterns suggest the drug can scale into a meaningful hypertrophic cardiomyopathy (HCM) franchise. The stock is trading at $83.26 today, reflecting high expectations. This trade idea targets label expansion…
